Evidence map›Paper›PMID 37798963›Full record

ReviewJournal of diabetes science and technology2025

Combining Glucose Monitoring and Insulin Infusion in an Integrated Device: A Narrative Review of Challenges and Proposed Solutions.

Michael Schoemaker, Anna Martensson, Julia K Mader, Kirsten Nørgaard, Guido Freckmann, Pierre-Yves Benhamou, Peter Diem, Lutz Heinemann

Registry-linked trialOpen access · hybridAbstract readReview
In one paragraph

Review in Journal of diabetes science and technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07655076 (Simultaneous Measurement and Responsive Treatment - Part 2), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07655076 early_phase1recruitingnot on this mapstarted 2026, after this paper: background citation

Simultaneous Measurement and Responsive Treatment - Part 2

TypeinterventionalSponsorClinSurge ResearchRan2026 to 2026Enrolled40ConditionsType 1 Diabetes Mellitus, T1D, Type 1 Diabetes, T1DMArmsDPP System (Insulin Pump and Continuous Glucose Monitoring Platform)
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. The Future of Automated Insulin Delivery Systems.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2025
    Review
  4. Article
  5. Review
  6. Diabetes Technology Meeting 2023.Journal of diabetes science and technology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 5 countries.

Michael SchoemakerPharmaSens AG, Biel, Switzerland.ORCID 0009-0007-9138-7085
Anna MartenssonPharmaSens AG, Biel, Switzerland.
Julia K MaderMedical University of Graz, Graz, Austria.ORCID 0000-0001-7854-4233
Kirsten NørgaardSteno Diabetes Center Copenhagen, Herlev, Denmark.ORCID 0000-0003-1620-8271
Guido FreckmannInstitut für Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Ulm, Germany.ORCID 0000-0002-0406-9529
Pierre-Yves BenhamouDepartment of Endocrinology, Grenoble University Hospital, Grenoble Alpes University, Grenoble, France.ORCID 0000-0003-4378-0468
Peter DiemArtificial Intelligence in Health and Nutrition, ARTORG Center for Biomedical Engineering Research, University of Bern, Bern, Switzerland.
Lutz HeinemannScience-Consulting in Diabetes GmbH, Düsseldorf, Germany.ORCID 0000-0003-2493-1304
Centre Hospitalier Universitaire de Grenoble · FRMedical University of Graz · ATUniversität Ulm · DEUniversity of Bern · CHUniversity of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The introduction of automated insulin delivery (AID) systems has enabled increasing numbers of individuals with type 1 diabetes (T1D) to improve their glycemic control largely. However, use of AID systems is limited due to their complexity and costs associated. The user must wear both a continuously monitoring glucose system and an insulin infusion pump. The glucose sensor and the insulin catheter must be inserted at two different body sites using different insertion devices. In addition, the user must pair and manage the different systems. These communicate with the AID software implemented on the pump or on a third device such as a dedicated display device or smart phone application. These components might be developed and commercialized by different manufacturers, which in turn can cause difficulties for patients seeking technical support. A possible solution to these challenges would be to integrate the glucose sensor and insulin catheter into a single device. This would allow the glucose sensor and insulin catheter to be inserted simultaneously, eliminating the need for pairing, and simplifying system management. In recent years, different technologies have been developed and evaluated in clinical investigations that combine the glucose sensor and the insulin catheter in one platform. The consistent finding of all these studies is that integration has no adverse effect on insulin infusion and glucose measurements provided that certain conditions are met. In this review, we discuss the perceived challenges of such an approach and discuss possible solutions that have been proposed.

Indexed as

Blood GlucoseBlood Glucose Self-MonitoringDiabetes Mellitus, Type 1Hypoglycemic AgentsInsulinInsulin Infusion SystemsEquipment DesignHumansBlood GlucoseHypoglycemic AgentsInsulinaccuracyautomated insulin deliverycolocalizationcontinuous glucose monitoringinsulin deliveryintegration

Identifiers

PMID37798963
PMCPMC11874455
OpenAlexW4387393385

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.